To close out #BloodCancerAwarenessMonth, Hua-Jay Cherng from Columbia joined Allogene’s CMO, Zach Roberts, to discuss the LBCL patient journey, unmet need in first-line consolidation care, and the importance of expanding access to potentially lifesaving products. Thank you Dr. Cherng for joining us! #CART #immunotherapy
Allogene Therapeutics
Biotechnology
South San Francisco, California 66,580 followers
About us
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- Website
-
www.allogene.com
External link for Allogene Therapeutics
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune
Locations
-
Primary
210 E Grand Ave
South San Francisco, California 94080, US
-
7400 Gateway Blvd
Newark, California 94560, US
Employees at Allogene Therapeutics
Updates
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver "off-the-shelf" #CART products that do what autologous CAR T therapies cannot. #celltherapy #immunotherapy #STATSummit Explore Innovation at Allogene: Allogene.com/Science
-
Looking forward to having our own Dr. Zachary Roberts, Head of R&D and Chief Medical Officer, join the 2024 STAT Summit to discuss new frontiers in #CART innovation. #celltherapy #immunotherapy #STATSummit Join Us: https://lnkd.in/gQj2wZEw
-
Thoroughly enjoyed participating in this lively panel discussion at the Fierce Biotech Summit in Boston. Biotech can be challenging work for communicators but there is no place we would rather be. #CART #celltherapy #immunotherapy $ALLO Learn more: https://lnkd.in/gtM6CwrF
-
As #BloodCancerAwareness Month comes to a close, we’d like to thank everyone who contributed and raised awareness. At Allogene, we continue to push forward towards our goals with patients at the forefront of our minds. Learn more about the potential of our lead investigational AlloCAR T™ product candidate available for front line #LBCL. #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
-
We are looking forward to participating in Goldman Sachs Cell Therapy Day where our CEO, Dr. David Chang, will join a panel on innovations in the #allogeneic cell therapy landscape #CAR T. https://lnkd.in/gjGfcRdz
-
We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: https://lnkd.in/gXiYrYPp
-
We look forward to presenting our first pre-clinical data highlighting the potential of ALLO-329, our allogeneic dual #CAR T for the treatment of #autoimmune diseases at the American College of Rheumatology (ACR) Convergence. #Immunotherapy #celltherapy https://lnkd.in/gPTr-nrh
-
#BCAM Trivia Tuesday: According to Yale Medicine, over half of all #bloodcancers diagnosed in adults is lymphoma, making it the most common form of blood cancer in U.S. adults. Allogene’s lead #LBCL program hopes to treat patients suffering from #lymphoma. #CART #celltherapy #immunotherapy Learn About AlloCAR T Products: https://lnkd.in/gXiYrYPp
-
#BCAM Trivia Tuesday: In the U.S., what is the most common type of blood cancer in adults? Submit your guess below and watch for the answer. 1. Lymphoma 2. Leukemia 3. Myeloma